GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qyuns Therapeutics Co Ltd (HKSE:02509) » Definitions » Cash Conversion Cycle

Qyuns Therapeutics Co (HKSE:02509) Cash Conversion Cycle : 0.00 (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Qyuns Therapeutics Co Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Qyuns Therapeutics Co's Days Sales Outstanding for the three months ended in Dec. 2024 was .
Qyuns Therapeutics Co's Days Inventory for the three months ended in Dec. 2024 was .
Qyuns Therapeutics Co's Days Payable for the three months ended in Dec. 2024 was .
Therefore, Qyuns Therapeutics Co's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2024 was 0.00.


Qyuns Therapeutics Co Cash Conversion Cycle Historical Data

The historical data trend for Qyuns Therapeutics Co's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qyuns Therapeutics Co Cash Conversion Cycle Chart

Qyuns Therapeutics Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Cash Conversion Cycle
- - - -428.51

Qyuns Therapeutics Co Quarterly Data
Dec21 Dec22 Sep23 Dec23 Jun24 Dec24
Cash Conversion Cycle Get a 7-Day Free Trial - - - - -

Competitive Comparison of Qyuns Therapeutics Co's Cash Conversion Cycle

For the Biotechnology subindustry, Qyuns Therapeutics Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qyuns Therapeutics Co's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Qyuns Therapeutics Co's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Qyuns Therapeutics Co's Cash Conversion Cycle falls into.


;
;

Qyuns Therapeutics Co Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Qyuns Therapeutics Co's Cash Conversion Cycle for the fiscal year that ended in Dec. 2024 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=60.41+19.74-508.66
=-428.51

Qyuns Therapeutics Co's Cash Conversion Cycle for the quarter that ended in Dec. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=+-
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Qyuns Therapeutics Co  (HKSE:02509) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Qyuns Therapeutics Co Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Qyuns Therapeutics Co's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Qyuns Therapeutics Co Business Description

Traded in Other Exchanges
N/A
Address
No. 907 Yaocheng Avenue, Room 1310, Building 1, Taizhou, Jiangsu, CHN
Qyuns Therapeutics Co Ltd is a a clinical-stage biotech company focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline.
Executives
Tai Zhou Yi Yao Cheng Kong Gu Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Tai Zhou Jian Xin Chuang Ye Tou Zi You Xian Gong Si 2101 Beneficial owner
Hang Zhou Zhong Mei Hua Dong Zhi Yao You Xian Gong Si 2101 Beneficial owner
Zhong Guo Yuan Da Ji Tuan You Xian Ze Ren Gong Si 2201 Interest of corporation controlled by you
Tai Zhou Yi Yao Gao Xin Ji Shu Chan Ye Tou Zi Fa Zhan You Xian Gong Si 2201 Interest of corporation controlled by you
Tai Zhou Yi Yao Gao Xin Qu Hua Yin Jin Rong Tou Zi You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Yuan Da Hua Chuang Tou Zi You Xian Gong Si 2201 Interest of corporation controlled by you
Hua Dong Yi Yao Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Qiu Jiwan
Xu Qiu
Hangzhou Quanyi Investment Management Partnership (general Partnership)
Yu Guo'an
Zhu Jing
Taizhou Xinfu Tongxin Enterprise Management Partnership (limited Partnership)
Sheng Xi Tai

Qyuns Therapeutics Co Headlines

No Headlines